Article Text

Download PDFPDF

Changes in the molecular size distribution and post-transfusion survival of hydroxyethyl starch 350/0.60 as influenced by a lower degree of hydroxyethylation: a study in normal man.
  1. J M Mishler,
  2. C R Ricketts,
  3. E J Parkhouse


    The need to provide a greater rate of colloid clearance from blood than is presently available with the long-acting dosage form of HES 450/0.70 prompted the clinical investigation of a new species of hydroxyethyl starch (HES) possessing a M-w of 350000 concomitant with a molar substitution of 0.60 (HES 350/0.60). The concentration of HES 350/0.60 in serum fell to half its peak value in 10.2 +/- 0.7 (SD) hour (in contrast to an IT50 of approximately 25 hours with HES 450/0.70). Levels of glucose in serum remained elevated in normal fasted subjects after dosing, suggesting that catabolism of the infused HES 350/0.60 was occurring. Hydrolysis of residual HES 350/0.60 was confirmed by Sepharose CL-4B gel filtration analysis of material obtained from serum, showing continual production of smaller molecules relative to the injected solution (in contrast to HES 450/0.70, in which intermediate polymer fragments are recovered). Recovered HES 350/0.60 material displayed a Kav ranging between 0.74 and 0.72 and possessed a Stokes radius (r = 45A) similar to that of dextran 40 (M-w 41000). HES 350/0.69 appears to offer the same advantages as the currently available long-acting HES 450/0.70 but is removed from blood approximately twice as rapidly. This more rapid hydrolysis of HEs 350/0.60 may be useful, for example, in avoiding cumulative build-up of colloid in the blood of normal donors undergoing consecutive leucapheresis procedures.

    Statistics from

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.